Search research articles
Contact Us
Filters
Showing results (31-40 of 112) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
May 30, 2012
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
Alan K Burnett, Nigel H Russell, Dominic Culligan, et al.
British Journal of Haematology
|
April 7, 2022
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial
Nigel H Russell, Robert K Hills, Lars Kjeldsen, et al.
Oncotarget
|
January 18, 2018
A molecular signature of dormancy in CD34<sup>+</sup>CD38<sup>-</sup> acute myeloid leukaemia cells
Mazin Gh Al-Asadi, Grace Brindle, Marcos Castellanos, et al.
The Lancet. Oncology
|
February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial
Birte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
Haematologica
|
October 14, 2021
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Nigel H Russell, Robert K Hills, Abin Thomas, et al.
Haematologica
|
November 4, 2005
The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors
Bronwen E Shaw, Nigel H Russell, Steve Devereux, et al.
Blood
|
December 13, 2017
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
Rosemary E Gale, Teodora Popa, Melissa Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Frontiers in Immunology
|
November 19, 2019
Non-uniform <i>in vivo</i> Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease
David M Burns, Gordon B Ryan, Caroline M Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
Alan K Burnett, Robert K Hills, Donald Milligan, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 112) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
May 30, 2012
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
Alan K Burnett, Nigel H Russell, Dominic Culligan, et al.
British Journal of Haematology
|
April 7, 2022
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial
Nigel H Russell, Robert K Hills, Lars Kjeldsen, et al.
Oncotarget
|
January 18, 2018
A molecular signature of dormancy in CD34<sup>+</sup>CD38<sup>-</sup> acute myeloid leukaemia cells
Mazin Gh Al-Asadi, Grace Brindle, Marcos Castellanos, et al.
The Lancet. Oncology
|
February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial
Birte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
Haematologica
|
October 14, 2021
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Nigel H Russell, Robert K Hills, Abin Thomas, et al.
Haematologica
|
November 4, 2005
The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors
Bronwen E Shaw, Nigel H Russell, Steve Devereux, et al.
Blood
|
December 13, 2017
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
Rosemary E Gale, Teodora Popa, Melissa Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Frontiers in Immunology
|
November 19, 2019
Non-uniform <i>in vivo</i> Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease
David M Burns, Gordon B Ryan, Caroline M Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
Alan K Burnett, Robert K Hills, Donald Milligan, et al.
Page
of 12